A study of the pharmacokinetic profile of low-dose @entity1956 immune globulin in long-term liver transplant recipients for chronic XXXX .

@entity1 @entity97 @entity16332 @entity1956
Post-transplant protocols for @entity1956 ( @entity97 ) prophylaxis using high-dose intravenous @entity1956 immune globulin (10,000 IU) with or without @entity16332 are commonly reported. Our centre has previously reported a low-dose intramuscular (i.m.) protocol and @entity16332 with excellent results. There have been, however, no pharmacokinetic studies of i.m. @entity1956 immune globulin (HBIG) in this setting. The objective of this study was to determine the pharmacokinetic profile of i.m. HBIG in long-term post-liver-transplant recipients to determine a rational dosing protocol. Six stable liver transplant recipients receiving monthly i.m. HBIG injections for greater than one year were enrolled in this study. All @entity1 had no detectable @entity97 DNA levels. HBIG titers (anti-HBs) were measured predose, then three times weekly for four weeks and then twice weekly until the serum HBIG titers were 100 IU/L or less. The pharmacokinetic parameters were calculated using noncompartment methods. The mean time to maximum concentration was 10.5 d (range 4-20 d) and the mean half-life was 20 d (range 13.5-23.5 d). Based on these pharmacokinetic parameters in stable long-term post-transplant @entity1 , a rational dosing protocol was developed that allows for more appropriate utility of HBIG and improved @entity1 convenience.
